Evaluation of Drug Candidates for Preclinical Development
Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology
Erschienen am 14. Januar 2010
256 Seiten
978-0-470-57488-1 (ISBN)
Beschreibung
Emphasizes the integration of major areas of drug discovery andtheir importance in candidate evaluation
It is believed that selecting the "right" drug candidate fordevelopment is the key to success. In the last decade,pharmaceutical R&D departments have integrated pharmacokineticsand drug metabolism, pharmaceutics, and toxicology into early drugdiscovery to improve the assessment of potential drug compounds.Now, Evaluation of Drug Candidates for Preclinical Developmentprovides a complete view and understanding of whyabsorption-distribution-metabolism-excretion-toxicology (ADMET)plays a pivotal role in drug discovery and development.
Encompassing the three major interrelated areas in whichoptimization and evaluation of drug developability is mostcritical--pharmacokinetics and drug metabolism, pharmaceutics,and safety assessment--this unique resource encouragesintegrated thinking in drug discovery. The contributors to thisvolume:
* Cover drug transporters, cytochrome P-450 and drug-druginteractions, plasma protein binding, stability, drug formulation,preclinical safety assessment, toxicology, and toxicokinetics
* Address developability issues that challenge pharma companies,moving beyond isolated experimental results
* Reveal connections between the key scientific areas that arecritical for successful drug discovery and development
* Inspire forward-thinking strategies and decision-makingprocesses in preclinical evaluation to maximize the potential ofdrug candidates to progress through development efficiently andmeet the increasing demands of the marketplace
Evaluation of Drug Candidates for Preclinical Development servesas an introductory reference for those new to the pharmaceuticalindustry and drug discovery in particular. It is especially wellsuited for scientists and management teams in small- to mid-sizedpharmaceutical companies, as well as academic researchers andgraduate students concerned with the practical aspects related tothe evaluation of drug developability.
It is believed that selecting the "right" drug candidate fordevelopment is the key to success. In the last decade,pharmaceutical R&D departments have integrated pharmacokineticsand drug metabolism, pharmaceutics, and toxicology into early drugdiscovery to improve the assessment of potential drug compounds.Now, Evaluation of Drug Candidates for Preclinical Developmentprovides a complete view and understanding of whyabsorption-distribution-metabolism-excretion-toxicology (ADMET)plays a pivotal role in drug discovery and development.
Encompassing the three major interrelated areas in whichoptimization and evaluation of drug developability is mostcritical--pharmacokinetics and drug metabolism, pharmaceutics,and safety assessment--this unique resource encouragesintegrated thinking in drug discovery. The contributors to thisvolume:
* Cover drug transporters, cytochrome P-450 and drug-druginteractions, plasma protein binding, stability, drug formulation,preclinical safety assessment, toxicology, and toxicokinetics
* Address developability issues that challenge pharma companies,moving beyond isolated experimental results
* Reveal connections between the key scientific areas that arecritical for successful drug discovery and development
* Inspire forward-thinking strategies and decision-makingprocesses in preclinical evaluation to maximize the potential ofdrug candidates to progress through development efficiently andmeet the increasing demands of the marketplace
Evaluation of Drug Candidates for Preclinical Development servesas an introductory reference for those new to the pharmaceuticalindustry and drug discovery in particular. It is especially wellsuited for scientists and management teams in small- to mid-sizedpharmaceutical companies, as well as academic researchers andgraduate students concerned with the practical aspects related tothe evaluation of drug developability.
Weitere Details
Weitere Ausgaben
Personen
Chao Han, PHD, is Associate Director of Pharmacokinetics,Modeling and Simulation, Clinical Pharmacology Sciences, CentocorR&D. He has been working in drug discovery and earlydevelopment for more than ten years, published over thirty researcharticles in peer-reviewed journals, and written three bookchapters.
Charles B. Davis, PHD, heads Drug Metabolism andPharmacokinetics for the cancer Metabolism Drug Discovery Unitwithin Cancer Research at GlaxoSmithKline. He has more than twentyyears experience in preclinical and clinical development and hasserved on the leadership teams of three of GSK's Centers ofExcellence in Drug Discovery.
Binghe Want, PHD, is Professor and Georgia researchAlliance Eminent Scholar in Drug Discovery in the Department ofChemistry, Georgia State University and Georgia cancer CoalitionDistinguished Scientist. He also serves as editor in chief ofMedicinal research Reviews and is lead editor of Drug Delivery:Principles and Applications (Wiley).
Charles B. Davis, PHD, heads Drug Metabolism andPharmacokinetics for the cancer Metabolism Drug Discovery Unitwithin Cancer Research at GlaxoSmithKline. He has more than twentyyears experience in preclinical and clinical development and hasserved on the leadership teams of three of GSK's Centers ofExcellence in Drug Discovery.
Binghe Want, PHD, is Professor and Georgia researchAlliance Eminent Scholar in Drug Discovery in the Department ofChemistry, Georgia State University and Georgia cancer CoalitionDistinguished Scientist. He also serves as editor in chief ofMedicinal research Reviews and is lead editor of Drug Delivery:Principles and Applications (Wiley).
Inhalt
PREFACE.
CONTRIBUTORS.
1. INTRODUCTION (Charles B. Davis).
2. PHARMACOKINETICS IN PRECLINICAL DRUG DEVELOPMENT: ANOVERVIEW (Dion Brocks).
3. THE ROLE OF MEMBRANE TRANSPORTERS IN DRUG DISPOSITION(Fanfan Zhou, Peng Duan, and Guofeng You).
4. CYTOCHROME P450: STRUCTURE, FUNCTION, AND APPLICATION INDRUG DISCOVERY AND DEVELOPMENT (Ramesh B. Bambal and StephenE. Clarke).
5. THE ROLE OF DRUG METABOLISM AND METABOLITE IDENTIFICATIONIN DRUG DISCOVERY (Xiangming Guan).
6. PROTEIN BINDING IN DRUG DISCOVERY AND DEVELOPMENT(Vikram Ramanathan and Nimish Vachharajani).
7. PREDICTION OF THE PHARMACOKINETICS IN HUMANS (ChaoHan and Ramesh Bambal).
8. PHARMACEUTICS DEVELOPABILITY ASSESSMENT (LianHuang, Jinquan Dong, and Shyam Karki).
9. SAFETY ASSESSMENT IN DRUG DISCOVERY (Vito G.Sasseville, William R. Foster, and Bruce D. Car).
10. ASSESSMENT OF STRATEGIES UTILIZED TO MINIMIZE THEPOTENTIAL FOR INDUCTION OF ACQUIRED LONG QT SYNDROME AND TORSADE DEPOINTES (Khuram W. Chaudhary and Barry S. Brown).
INDEX.
CONTRIBUTORS.
1. INTRODUCTION (Charles B. Davis).
2. PHARMACOKINETICS IN PRECLINICAL DRUG DEVELOPMENT: ANOVERVIEW (Dion Brocks).
3. THE ROLE OF MEMBRANE TRANSPORTERS IN DRUG DISPOSITION(Fanfan Zhou, Peng Duan, and Guofeng You).
4. CYTOCHROME P450: STRUCTURE, FUNCTION, AND APPLICATION INDRUG DISCOVERY AND DEVELOPMENT (Ramesh B. Bambal and StephenE. Clarke).
5. THE ROLE OF DRUG METABOLISM AND METABOLITE IDENTIFICATIONIN DRUG DISCOVERY (Xiangming Guan).
6. PROTEIN BINDING IN DRUG DISCOVERY AND DEVELOPMENT(Vikram Ramanathan and Nimish Vachharajani).
7. PREDICTION OF THE PHARMACOKINETICS IN HUMANS (ChaoHan and Ramesh Bambal).
8. PHARMACEUTICS DEVELOPABILITY ASSESSMENT (LianHuang, Jinquan Dong, and Shyam Karki).
9. SAFETY ASSESSMENT IN DRUG DISCOVERY (Vito G.Sasseville, William R. Foster, and Bruce D. Car).
10. ASSESSMENT OF STRATEGIES UTILIZED TO MINIMIZE THEPOTENTIAL FOR INDUCTION OF ACQUIRED LONG QT SYNDROME AND TORSADE DEPOINTES (Khuram W. Chaudhary and Barry S. Brown).
INDEX.
